← Back to Search

NAD+ Boosting Product

Limitless for High Blood Pressure

Phase 2

Waitlist Available

Led By David Crowley, MD

Research Sponsored by Limitless Research Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 30

Awards & highlights

Study Summary

This trial will study the effects of Limitless, a supplement, on various measures of vascular function and safety in adults after 30 days of supplementation as part of a low-carbohydrate diet.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 30

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~30

This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Changes to blood nitrate from baseline to Day 30 post-supplementation with Limitless in addition to a low carbohydrate diet

Peroxynitrite

Changes to blood pressure from baseline to Day 30 post-supplementation with Limitless in addition to a low carbohydrate diet

+3 more

Secondary outcome measures

Changes to C-reactive protein from baseline to Day 30 post-supplementation with Limitless in addition to a low carbohydrate diet

Changes to C-reactive protein from pre- to 2.5-hours after acute dose supplementation with Limitless at baseline and at Day 30

Changes to L-arginine from pre- to 2.5-hours after acute dose supplementation with Limitless at baseline and at Day 30

+35 more

Other outcome measures

Change in Alanine Aminotransferase After 30 day supplementation with Limitless in addition to a low carbohydrate diet

Change in Amount of Basophils After 30 day supplementation with Limitless in addition to a low carbohydrate diet

Change in Amount of Eosinophils After 30 day supplementation with Limitless in addition to a low carbohydrate diet

+26 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: LimitlessExperimental Treatment1 Intervention

Participants will be instructed to take Limitless capsules for 30 days starting with the first dose to be administered in clinic on Visit 2 (Day 1, Baseline). The last dose will occur in clinic on Visit 3 (Day 30). Participants will be instructed to take two capsules two hours with water after breakfast, and two capsules two hours after dinner. Do not take food after evening dose before bed. (i.e. no snacking or desserts.). If a dose is missed participants are instructed to skip that dose. Participants will be advised not to exceed four capsules daily.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

KGK Science Inc.Industry Sponsor

78 Previous Clinical Trials

6,138 Total Patients Enrolled

Limitless Research Inc.Lead Sponsor

David Crowley, MDPrincipal InvestigatorKGK Science Inc.

35 Previous Clinical Trials

2,731 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Do I qualify to be an enrollee in this test?

"This medical study is taking applicants with hypertension aged 45-65. Approximately 22 people will be admitted into the trial."

Answered by AI

Are enrolment opportunities still available for this research program?

"Per the data hosted on clinicaltrials.gov, this medical trial is currently open for enrollment; it was initially declared in February of 2022 and its most recent update occurred in August of that same year."

Answered by AI

What is the upper limit for participants in this medical experiment?

"Indeed, clinicaltrials.gov records that this experiment is actively enrolling patients and has been advertised since February 23rd 2022 with an update occurring on August 24th of the same year. The trial necessitates 22 individuals from one medical facility to participate in it."

Answered by AI

For what purpose is this clinical trial primarily designed to investigate?

"The primary assessment of this study, which is to take place over a 30-day period, will be the modification in blood peroxynitrite levels from pre-supplementation with Limitless and a low carb diet. Secondary observations include alterations to high-density lipoprotein cholesterol, time to exhaustion, and the six minute walk test when compared against baseline measurements post supplementation."

Answered by AI

Are there any potential adverse outcomes associated with Limitless usage?

"Based on the data available, Limitless is rated a 2 for safety as this trial has only reached Phase 2. Although there are indications of its security, no proof exists to support its efficacy."

Answered by AI

Is the enrollment for this trial limited to adults or are minors also being enrolled?

"The criteria for enrolment in this clinical trial narrows the potential participants down to those between 45 and 65 years of age. There are 54 trials targeting subjects under 18, while 661 studies have been designed for seniors above 65."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

The Safety and Efficacy of an NAD+ Boosting Product Together With a Low Carbohydrate Diet in Adults With Mild Hypertension and Eligible for Normal-standard-of-care

2022. "The Safety and Efficacy of an NAD+ Boosting Product Together With a Low Carbohydrate Diet in Adults With Mild Hypertension and Eligible for Normal-standard-of-care". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05298410.